FDA Inspectors Focusing Attention On Traditional Manual Aseptic Filling Lines
Firms that manufacture sterile drugs on traditional filling lines instead of using restricted access barriers or isolators risk tighter scrutiny from FDA inspectors, agency official says. Yet it remains unclear how much of a difference the increased oversight will make.
You may also be interested in...
Despite the reduced risk of contaminating sterile drug products, most manufacturers are still not using advanced technologies such as RABS and isolators in the cleanroom. High costs and lack of regulatory pressure were cited in survey responses as reasons for the slow uptake.
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”